Carboplatin-Epirubicin Regimen for the Treatment of Hepatoblastomat

Pediatric Blood and Cancer

Volumn 42, Issue 2, 2004, Pages 149-154

  Blouin, P ^a,b   Brugières, Laurence ^a   Tabone, M D ^c   Leverger, G ^c   Rubie, H ^d   Branchereau, S ^e   De Kraker, J ^f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d CHU PURPAN   (France)

^e BICÊTRE HOSPITAL   (France)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Carboplatin; Chemotherapy; Epirubicin; Hepatoblastoma

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; EPIRUBICIN;

ADOLESCENT; ANEMIA; ARTICLE; BLEEDING; BONE MARROW TOXICITY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG EFFICACY; EPITHELIUM; FEVER; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; INFANT; INFECTION; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG METASTASIS; MUCOSA INFLAMMATION; NEPHROTOXICITY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VALIDATION PROCESS;

ADOLESCENT; ALPHA-FETOPROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; EPIRUBICIN; HEPATOBLASTOMA; HUMANS; INFANT; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0842268432     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Vos A. Primary liver tumours in children. Eur J Surg Oncol 1995;21:101-105.
2. Douglass EC. Hepatic malignancies in childhood and adolescence (hepatoblastoma, hepatocellular carcinoma, and embryonal sarcoma). Cancer Treat Res 1997;92:201-212.
3. Evans AE, Land VA, Newton WA, et al. Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoblastoma. Cancer 1982;50:821-826.
4. Douglass EC, Green A, Wrenn E, et al. Effective cisplatin based chemotherapy in the treatment of hepatoblastoma. Med Pediatr Oncol 1985;13:187-190.
5. Filler RM, Ehrlich PF, Greenberg ML, et al. Preoperative chemotherapy in hepatoblastoma. Surgery 1991;110:591-596.
6. Ortega JA, krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: A report from the children cancer study group. J Clin Oncol 1991;9:2167-2176.
7. Douglass EC, Reynolds M, Finegold M, et al. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: A paediatric oncology group study. J Clin Oncol 1993;11:96-99.
8. Shafford EA, Pritchard J. Hepatoblastoma - A bit of a success story? Eur J Cancer 1994;30A:1050-1051.
9. Ehrlich PE, Greenberg ML, Filler M. Improved long term survival with preoperative chemotherapy for hepatoblastoma. J Pediatr Surg 1997;32:999-1003.
10. Von Schweinitz D, Byrd DJ, Hecker H, et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer 1997;33:1243-1249.
11. Seo T, Ando H, Watanabe Y, et al. Treatment of hepatoblastoma: Less extensive hepatectomy after effective preoperative chemotherapy with cisplatin and adriamycin. Surgery 1998;123:407-414.
12. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin and delayed surgery for children hepatoblastoma: A successful approach results of the first prospective study of the international Society of Paediatric Oncology. J Clin Oncol 2000;18:3819-3828.
13. Ortega JA, Douglass JH, Reynolds MR, et al. Randomized comparison of cisplatinum/vincristine/fluorouracil and cisplatinum/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncolgy Group. J Clin Oncol 2000;18:2665-2675.
14. Brock P, Bellman S, Yeomans E, et al. Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 1991;19:295-300.
15. Daugaard G, Abidgaard U. Cisplatin nephrotoxocity. A review. Cancer Chemother Pharmacol 1989;25:1-9.
16. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-815.
17. Doz F, Pinkerton R. What is the place of carboplatin in paediatric oncology? Eur J Cancer 1994;30A:194-201.
18. The French Epirubicin Group. A prospective phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 1988;6:305-312.
19. Perilongo G, Shafford E, Plaschkes J. SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol 2000;1:94-100.
20. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.
21. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patients: II. Analysis and examples. Br J Cancer 1977;35:1-39.
22. Dall'Igna P, Cechetto G, Dominici C, et al. Carboplatin and doxorubicin (CARDOX) for nonmetastatic hepatoblastoma: A discouraging pilot study. Med Pediatr Oncol 2001;36:332-334.
23. Perilongo G, Shafford E, Brugières L, et al. Cisplatin (CDDP) alone and delayed surgery, an effective treatment for standard risk hepatoblastoma, the most relevant finding of the SIOPEL2.ASCO 2002, (Abstract 1571) Vol 21. 2002;393a.
24. Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: Results of the first prospective study of the international society of pediatric oncology group. J Clin Oncol 2002;20:2798-2804.
25. Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998;16:3502-3508.